tradingkey.logo
搜尋

MiMedx Group Inc

MDXG
添加自選
4.130USD
-0.140-3.28%
收盤 07-31 16:00美東報價延遲15分鐘
601.99M總市值
19.87本益比TTM

關於 MiMedx Group Inc 公司

MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.

MiMedx Group Inc簡介

公司代碼MDXG
公司名稱MiMedx Group Inc
上市日期Aug 20, 2007
CEOCapper (Joseph H)
員工數量837
證券類型Ordinary Share
年結日Aug 20
公司地址1775 W Oak Commons Court, Ne
城市MARIETTA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編30062
電話17706519100
網址https://mimedx.com/
公司代碼MDXG
上市日期Aug 20, 2007
CEOCapper (Joseph H)

MiMedx Group Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Chief Executive Officer, Director
Chief Executive Officer, Director
310.29K
-190.25%
Ms. Ricci S. Whitlow
Ms. Ricci S. Whitlow
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
284.25K
+28.78%
Mr. James L. Bierman
Mr. James L. Bierman
Independent Director
Independent Director
263.68K
+19.31%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
181.92K
--
Ms. Dorothy E. Puhy
Ms. Dorothy E. Puhy
Independent Director
Independent Director
108.51K
+46.92%
Ms. Kimberly (Kim) Maersk-Moller
Ms. Kimberly (Kim) Maersk-Moller
Chief Commercial Officer
Chief Commercial Officer
73.33K
-27.03%
Mr. William Frank (Butch) Hulse, IV
Mr. William Frank (Butch) Hulse, IV
Chief Administrative Officer, General Counsel
Chief Administrative Officer, General Counsel
--
--
Dr. M. Kathleen Behrens Wilsey, Ph.D.
Dr. M. Kathleen Behrens Wilsey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. K. Todd Newton
Mr. K. Todd Newton
Independent Director
Independent Director
--
--
Marty Sutter ,
Marty Sutter ,
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Chief Executive Officer, Director
Chief Executive Officer, Director
310.29K
-190.25%
Ms. Ricci S. Whitlow
Ms. Ricci S. Whitlow
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
284.25K
+28.78%
Mr. James L. Bierman
Mr. James L. Bierman
Independent Director
Independent Director
263.68K
+19.31%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
181.92K
--
Ms. Dorothy E. Puhy
Ms. Dorothy E. Puhy
Independent Director
Independent Director
108.51K
+46.92%
Ms. Kimberly (Kim) Maersk-Moller
Ms. Kimberly (Kim) Maersk-Moller
Chief Commercial Officer
Chief Commercial Officer
73.33K
-27.03%

常見問題

MiMedx Group Inc的前五大股東是誰?

MiMedx Group Inc的前五大股東如下:Mr. Joseph H. (Joe) Capper

有多少機構持有MiMedx Group Inc(MDXG)的股份?

截至2026Q1,共有462家機構持有MiMedx Group Inc的股份,合計持有的股份價值約為116.77M,占公司總股份的78.40% 。與2025Q4相比,機構持股有所增加,增幅為6172968.00。

哪個業務部門對MiMedx Group Inc的收入貢獻最大?

在2026Q1,Advanced Wound Care業務部門對MiMedx Group Inc的收入貢獻最大,創收276.33M,占總收入的66.01% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有